Multiomics: Fueling Breakthroughs in Cancer Research

Cancer is a complex disease that can’t be explained by any single factor. Dynamic interactions between cancer cells and their microenvironments influence all levels of cellular regulation, including the genome, epigenome, transcriptome, and proteome. All of which, can be profiled using next-generation sequencing (NGS). Combined analysis of several levels of regulation through multiomics directly measures the causes and consequences of cancer phenotypes. Each layer of “omics” information reveals unique insight into cancer biology.


A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond.

*Data calculations on file. Illumina, Inc., 2015.

View customer spotlight videos

View Illumina webinars

View Illumina product videos

View Illumina support videos